PIL – FDA Warning Letter, Sep 10, 2020

The FDA issued a Warning Letter to www.bluepillmedications.com on September 2, 2020, for offering opioids for sale to U.S. consumers in violation of the Federal Food, Drug, and Cosmetic Act. The FDA determined that the website introduces misbranded and unapproved new drugs into interstate commerce, citing sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FD&C Act. The products are considered unapproved new drugs because they are not generally recognized as safe and effective for their labeled uses and lack prior FDA approval, violating sections 301(d) and 505(a). For instance, tramadol manufactured by "Dimedics" is offered without an approved application, despite FDA-approved versions bearing a black box warning for severe risks like addiction and respiratory depression. Furthermore, the drugs are misbranded under section 502(f)(1) because their labeling fails to bear adequate directions for use, as they are prescription drugs not suitable for self-diagnosis, violating section 301(a). Crucially, the website offers prescription drugs like tramadol without requiring a prescription, jeopardizing patient safety and misbranding the drugs under section 503(b)(1), which also constitutes a violation of section 301(k). The FDA emphasizes the inherent risks of unapproved and misbranded drugs, including contamination, counterfeiting, and inconsistent active ingredients, especially given the opioid epidemic. The firm is required to immediately cease offering violative drugs and notify the FDA within 15 working days of corrective actions taken to prevent recurrence. Failure to comply may lead to regulatory actions such as seizure or injunction.